Rifapentine Tablet, Film Coated shortage (resolved)
Rifapentine Tablet, Film Coated is not in an active FDA shortage right now. The most recent status on record was “Resolved”. This page is kept for history. This page was last refreshed from FDA data on Sep 21, 2026.
Rifapentine Tablet, Film Coated is not in an active FDA shortage right now (last status: “Resolved”) — confirm current availability with your pharmacy.
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Rifapentine Tablet, Film Coated. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Aug 6, 2026Shortage resolvedFDA no longer lists this as an active shortage.
-
Mar 25, 2020First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Sanofi-Aventis U.S. LLC 📞 800-633-1610 Option 7 1 NDC click to expand
| Status | NDC / product | Strength / size | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Resolved | Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24) | — | — | — | — |
These rows are manufacturer reports to the FDA for Rifapentine Tablet, Film Coated — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Rifapentine Tablet, Film Coated? options further down this page.
Why is Rifapentine Tablet, Film Coated in shortage?
Rifapentine (Priftin) 150 mg tablets from Sanofi-Aventis are currently listed on the FDA's drug shortage page, but I want to be straightforward with you — the manufacturer did not share a specific public reason for why it's on the list. That happens sometimes, and it can feel a little frustrating when you're looking for a clear answer.
What I can tell you is that the 150 mg film-coated tablets (the 24-tablet package, NDC 0088-2102-24) from Sanofi-Aventis are currently listed as available. So while this product appears in the shortage database, the manufacturer is reporting that it can still be obtained right now.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Rifapentine Tablet, Film Coated, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Rifapentine Tablet, Film Coated?
Rifapentine (sold as Priftin) is currently on the FDA drug-shortage list, but the supply picture here is steady. The 150 mg film-coated tablet—the only strength on this record—is reported as available from its manufacturer. No strength is listed as having no source right now.
This shortage has been on the books for over a year, which can look concerning at first glance. In practice, though, the single manufacturer on this record (Sanofi-Aventis) continues to report the 150 mg tablet as available, and none of the listed product codes are marked unavailable. Overall supply risk is rated medium. National data like this reflects manufacturer reports and may not perfectly match what any one pharmacy has on its shelf at a given moment.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own. Keep taking it as prescribed.
- Since your 150 mg strength still has supply, ask your pharmacy to order it—they can check wholesalers and the manufacturer.
- If your pharmacy has trouble locating it, ask your prescriber or pharmacist about your options.
- The manufacturer's contact number is listed on this page for reference; pharmacies usually handle those calls.
This is general information, not advice tailored to you. Your pharmacist can confirm what is actually in stock locally.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Other drugs in the same treatment class
These are different medicines — not other versions of Rifapentine Tablet, Film Coated — that fall in the same broad treatment class (antitubercular antibiotics) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other anti-infective shortages
Rifapentine Tablet, Film Coated shortage FAQs
Is Rifapentine Tablet, Film Coated in shortage?
Which products are affected?
When will Rifapentine Tablet, Film Coated be available again?
What should I do if I take Rifapentine Tablet, Film Coated?
Still have a question about the Rifapentine Tablet, Film Coated shortage?
Ask a pharmacist about this shortage →View Rifapentine Tablet, Film Coated on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.